3-Dimensional virtual ventricles to design precision therapies in hypertrophic cardiomyopathy

3 维虚拟心室设计肥厚型心肌病的精准疗法

• 批准号: 10381681
• 负责人: JONATHAN MORENO
• 金额: $ 14.3万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10381681
• 关键词: 3-Dimensional; Address; Adrenergic Agents; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Architecture; Arrhythmia; Award; Biophysics; Calcium Channel Blockers; Cardiac; Cardiac Electrophysiologic Techniques; Cardiac Myocytes; Cardiology; Cardiomyopathies; Cardiovascular system; Cell Therapy; Cell model; Cells; Clinical; Clinical Data; Clinical Trials; Combination Drug Therapy; Combined Modality Therapy; Computer Models; Coupled; Data; Disease; Disopyramide; Doctor of Philosophy; Drug Combinations; Echocardiography; Electrophysiology (science); Failure; Fibrosis; Functional disorder; Genes; Genetic; Genotype; Geometry; Goals; Heart; Heart Abnormalities; Heart Diseases; Heart Transplantation; Heart failure; Human; Hypertrophic Cardiomyopathy; Image; Imaging Techniques; Inherited; Internal Medicine; Knowledge; Lead; Light; Link; Literature; Medical; Medical Genetics; Medicine; Mentorship; Microvascular Dysfunction; Modeling; Molecular; Multimodal Imaging; Muscle Cells; Mutation; National Heart, Lung, and Blood Institute; Obstruction; Optics; Organ; Pathologic; Pathway interactions; Patients; Pattern; Persons; Pharmaceutical Preparations; Pharmacotherapy; Phenotype; Precision therapeutics; Propranolol; Quality of life; Research; Research Personnel; Research Priority; Resources; Signal Pathway; Signal Transduction; Sodium; Specimen; Sudden Death; Symptoms; Testing; Therapeutic; Time; Tissues; Training; Ventricular; Ventricular Arrhythmia; Ventricular Remodeling; biophysical properties; cardiac magnetic resonance imaging; design; drug efficacy; drug testing; heart rhythm; high dimensionality; indium arsenide; insight; instructor; interdisciplinary approach; mortality; novel; novel therapeutics; optical imaging; patient response; preclinical study; predictive test; prevent; prospective; ranolazine; response; scaffold; skills; success; sudden cardiac death; targeted treatment; three-dimensional modeling; tool; virtual

Project Abstract Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease worldwide and is the leading cause of sudden cardiac death (SCD) in young people. Though HCM is characterized by more than 1400 mutations in the genes encoding the contractile apparatus of the cell, the pathophysiology of HCM encompasses diverse clinical symptoms; it can eventually lead to heart failure and fatal ventricular arrhythmia. Despite nearly 5 decades of research, there is currently no disease-modifying or mortality-reducing drug therapy for HCM patients. HCM treatment has failed for two key reasons: (1) arrhythmias are an emergent phenomena in space and time: single cell markers of arrhythmia fail to predict the effects on the whole heart; and (2) HCM is markedly heterogeneous - it is likely there are specific molecular underpinnings leading to differential drug efficacy that are not appreciated in large clinical trials and preclude a “one-size-fits-all” approach. I hypothesize that the key to understanding the therapeutic potential of drug therapy for HCM is through patient-specific modeling of their cardiac electrophysiology and ventricular ultrastructure. Thus, the goal of this research award is to merge clinical data, genetics, advanced imaging, and biophysical characterization of HCM to understand how higher dimensional ultrastructural remodeling influences cellular electrophysiology to design precision-targeted drug therapy. Specifically, I will develop a detailed electrophysiologic model of HCM that recapitulates mutation-specific alterations to better understand key determinants of success and failure for drug therapy. I will study patient-specific responses to two test drugs: ranolazine and b-blockers by optical imaging of dissociated adult cardiomyocytes of patients with HCM. I will then use multimodal imaging to characterize ventricular geometry and myofiber architecture of these patients to create a 3D virtual ventricle to test our single cell drug predictions. These aims will allow us me understand the bidirectional relationship between ventricular remodeling and single cell electrophysiology and drug therapy. I believe I have the appropriate background and resources to address the knowledge gaps described but require additional mentorship and training to transition to independence. I previously earned a PhD in computational cardiology and have undertaken additional training in basic and translational cardiovascular research. I have completed clinical training in Internal Medicine, Cardiology, Echocardiography, and Advanced Heart Failure and Cardiac Transplant, and have been appointed Instructor of Medicine as of July 1, 2020. To transition to an independent investigator, this K08 award will allow me to focus on developing new experimental skillsets in cellular electrophysiology, optical imaging techniques, as well as cardiac MRI and echo imaging that will compliment his computational background. At the conclusion of this award period, I will have acquired the skills to become a leader in translational characterization of heart failure and cardiomyopathies with the ultimate goal of designing novel therapies for patients suffering from these diseases.

项目摘要 肥厚性心肌病（HCM）是全球最常见的遗传性心脏病，是 年轻人突然心脏死亡（SCD）的主要原因。尽管HCM的特征是超过1400 编码细胞收缩仪的基因中的突变，HCM的病理生理 潜水员临床症状；有时会导致心力衰竭和致命的心室心律不齐。尽管差不多 5年的研究，目前尚无HCM疾病修改或减少死亡率的药物治疗 患者。 HCM治疗失败的原因有两个：（1）心律不齐是太空中的紧急现象 和时间：心律不齐的单细胞标记无法预测对整个心脏的影响； （2）HCM明显 异质性 - 可能存在特定的分子基础，导致药物效率差异，以至于 在大型临床试验中不受欢迎，并排除了“一定大小的所有”方法。 我假设了解HCM药物治疗的治疗潜力的关键是 其心脏电生理学和心室超微结构的患者特异性建模。那是这个目标 研究奖是合并临床数据，遗传学，高级成像和生物物理表征 HCM的了解高维超微结构重塑如何影响细胞 电生理设计精确的药物治疗。具体来说，我将开发一个详细的 HCM的电生理模型，该模型概括了突变特异性变化以更好地理解密钥 药物治疗成功和失败的决定因素。我将研究对两种测试药物的患者特定反应： 雷诺嗪和B阻滞剂通过对HCM患者解离的成年心肌细胞的光学成像。我会 然后使用多模式成像来表征这些患者的心室几何形状和肌纤维结构 创建一个3D虚拟心室以测试我们的单细胞药物预测。这些目标将使我了解 心室重塑与单细胞电生理学和药物治疗之间的双向关系。 我相信我有适当的背景和资源来解决所描述的知识差距，但是 需要额外的心态和训练才能过渡到独立性。我以前获得了博士学位 计算心脏病学，并在基本和翻译的心血管上接受了其他培训 研究。我已经完成了内科，心脏病学，超声心动图和先进的临床培训 心力衰竭和心脏移植，截至2020年7月1日，已被任命为医学教练。 过渡到独立调查员，该K08奖将使我专注于开发新的实验性 细胞电生理学，光学成像技术以及心脏MRI和ECHO的技能 成像会补充他的计算背景。在此颁奖期结束时，我将 已经获得了成为心力衰竭和心肌病的转化表征领导者的技能 最终目标是为患有这些疾病的患者设计新型疗法。